Sugi Predict

Sugi Predict / Compounds / SCHEMBL6481265

SCHEMBL6481265

SCHEMBL6481265

CC(C)(C)OC(=O)N1C(Cc2ccc(Oc3cccc4ccccc34)cc2)COC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CARM1 Q86X55 1/20 0.43
▸ PRMT6 Q96LA8 1/20 0.43
▸ MMP1 P03956 2/20 0.42
▸ MMP13 P45452 2/20 0.42
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ SCN1A P35498 2/20 0.36
▸ SCN2A Q99250 2/20 0.36
▸ SCN3A Q9NY46 2/20 0.36
▸ SPHK1 Q9NYA1 1/20 0.35
▸ NR1H2 P55055 2/20 0.35
▸ NR1H3 Q13133 2/20 0.35
▸ P2RX7 Q99572 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481261 1.00 CARM1 (0.43) CARM1PRMT6MMP1MMP13KMT2A
SCHEMBL6487562 0.86 SPHK1 (0.39) MAPTHPGDSMN1; SMN2SPHK1NR1H2
SCHEMBL6487557 0.86 SPHK1 (0.39) MAPTHPGDSMN1; SMN2SPHK1NR1H2
SCHEMBL2288435 0.86 SPHK1 (0.39) MAPTHPGDSMN1; SMN2SPHK1NR1H2
SCHEMBL6492398 0.86 SSTR4 (0.39) ADAM17
SCHEMBL2295708 0.84 NR1H2 (0.39) KMT2AMAPTHPGDSMN1; SMN2SPHK1
SCHEMBL2295715 0.84 NR1H2 (0.39) KMT2AMAPTHPGDSMN1; SMN2SPHK1
SCHEMBL2291830 0.83 SMN1; SMN2 (0.40) KMT2AMEN1LMNAMAPTSMN1; SMN2
SCHEMBL6479435 0.82 MEN1 (0.38) KMT2AMEN1SPHK1NR1H2NR1H3
SCHEMBL6479431 0.82 MEN1 (0.38) KMT2AMEN1SPHK1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 — — US disclosed
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-10-03 — — US disclosed
EP-1140849-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 — — EP disclosed
WO-2000040560-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB2, ADRB3 CARM1 1073/4885PRMT6 3286/4885MMP1 4194/4885
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB2, ADRB1, ADRB3 CARM1 701/4885PRMT6 2831/4885MMP1 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.